Atopic Dermatitis Topical Agents
Indications for Prior Authorization
Eucrisa (crisaborole) ointment
-
For diagnosis of Atopic Dermatitis
Indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
Criteria
Eucrisa
Step Therapy
Length of Approval: 12 Month(s)
For diagnosis of Atopic Dermatitis
- Trial and failure of a minimum 30-day supply (14-day supply for topical corticosteroids), contraindication, or intolerance to ONE of the following [2]:
- Medium or higher potency topical corticosteroid
- Generic topical calcineurin inhibitor (e.g., tacrolimus ointment)
P & T Revisions
2025-02-09, 2024-01-31, 2023-01-29, 2022-01-23, 2021-06-01, 2021-01-19, 2020-03-31, 2020-02-12
References
- Eucrisa Prescribing Information. Pfizer, Inc. New York, NY. April 2023.
- Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023; Epub ahead of print.
Revision History
- 2025-02-09: Updated step verbiage to align with other atopic dermatitis agents, including reducing the trial duration for a topical corticosteroid from 30 days to 14 days
- 2024-01-31: Annual review - no criteria changes; background updates
- 2023-01-29: Annual review - no criteria changes
- 2022-01-23: Annual review - no criteria changes
- 2021-06-01: Program update to allow for trial of a topical calcineurin inhibitor.
- 2021-01-19: Annual Review: added minimum trial and failure duration verbiage
- 2020-03-31: Program Update
- 2020-02-12: Annual Review
HEALTHY LIVING